

March 2023

### **Disclosure Statement from Leemore Dafny**

**Re:** “How Do Copayment Coupons Affect Branded Drug Prices and Quantities Purchased?”

Below are disclosure notifications for the paper referenced above which has been submitted for possible publication in the American Economic Review. These answers below respond to the five specific numbered questions contained in the American Economic Association disclosure document (<https://www.aeaweb.org/journals/policies/disclosure-policy>).

1. I did not receive any financial support for my work on the paper referenced above.
2. I have received payments for economic consulting in the past three years from Bates White Economic Consulting, Analysis Group, and Cornerstone Research. To the best of my knowledge, none of these firms has any stake in the paper referenced above, although some clients have businesses that could be impacted by hypothetical policy reforms discussed in the article. I am currently serving as an expert for the U.S. Department of Justice regarding allegations connected to pharmaceutical manufacturers’ relationship with copay assistance charities. Otherwise I have no relevant material or financial interests relating to this research.
3. I am not an officer, director, or board member in a profit or non-profit organization that has a relevant relationship to the contents of the article referenced above.
4. None of my close relatives have received any financial support for my work on the paper referenced above. None of my close relatives have received any financial support in the past three years from a party that would have a financial, ideological, or political stake in the paper referenced above. None of my close relatives are an officer, director, or board member in a profit or non-profit organization that has a relevant relationship to the contents of the article referenced above.
5. The only parties that have had the right to review the contents of the paper prior to circulation are our data sources: the Health Care Cost Institute and the Pharmaceutical Benefits Manager described in the article. This was only to ascertain that the written paper does not disclose any confidential information, and in the case of the PBM, to “decide whether to grant or deny permission to reveal the organization’s name in the scholarly work.”

